Association of oral calcitriol with improved survival in non-dialysed and dialysed patients with CKD

Nephrology Dialysis Transplantation

Volumn 24, Issue 2, 2009, Pages 341-344

  Negri, Armando L ^a,b  

^a UNIVERSIDAD DEL SALVADOR   (Argentina)

^b Instituto de Investigaciones Metabolicas   (Argentina)

Author keywords

Haemodialysis; Oral calcitriol; Predialysis; Survival

Indexed keywords

ALFACALCIDOL; CALCITRIOL; DOXERCALCIFEROL; PARICALCITOL;

BLOOD VESSEL CALCIFICATION; CHRONIC KIDNEY DISEASE; GLOMERULUS FILTRATION RATE; HEMODIALYSIS; HUMAN; HYPERCALCEMIA; HYPERPARATHYROIDISM; LOW DRUG DOSE; NOTE; PRIORITY JOURNAL; SURVIVAL RATE;

ADMINISTRATION, ORAL; CALCITRIOL; HUMANS; KIDNEY FAILURE, CHRONIC; RECEPTORS, CALCITRIOL; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; SURVIVAL RATE;

EID: 58449132325     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfn624     Document Type: Note

References (24)

1. Holick MF. Vitamin D: importance in prevention of cancers, type 1 diabetes, heart disease and osteoporosis. Am J Clin Nutr 2004; 79: 362-371
2. Boonstra A, Barrat FJ, Crain C et al. 1 alfa,25-dihydroxyvitamin D3 has a direct effect on naïve CD4+ T cells to enhance the development of Th2 cells. J immunol 2001; 167: 4974-4980
3. Li AC, Glass CK. The macrophage foam cell as a target for therapeutic intervention. Nat Med 2002; 8: 1235-1242
4. Barrat FJ, Cua DJ, Boonstra A et al. In vitro generation of interleukin 10-producing regulatory CD4+ cells is induced by immunosuppressive drugs and inhibited by T helper type1 (Th1) and Th2 inducing cytokines. J Exp Med 2002; 19: 603-616
5. Aihara K, Azuma H, Akaike M et al. Disruption of nuclear vitamin D receptor gene causes enhanced thrombogenicity in mice. J Biol Chem 2004; 279: 35798-35802
6. Wu J, Garami M, Cheng T et al. 1,25 (OH)2 vitamin D3 and retinoic acid antagonize endothelin stimulated hypertrophy of neonatal rat cardiac myocytes. J Clin Invest 1996; 97: 1577-1588
7. Li Q, Gardner DG. Negative regulation of the human atrial natriuretic peptide gene, by 1,25 dihydroxyvitamin D3. J Biol Chem 1994; 269: 493-4334
8. Chen S, Wu J, Hsieh JC et al. Suppression of ANP gene transcription by liganded vitamin D receptor: involvement of specific receptor domains. Hypertension 1998; 31: 1338-1342
9. Li YC, Qiao G, Uskokovic M et al. Vitamin D: a negative regulator of the renin-angiotensin system and blood pressure. J Steroid Biochem Mol Biol 2004; 89-90: 387-392
10. Baynes KC, Boucher BJ, Feskens EJ et al. Vitamin D, glucose tolerance and insulinemia in elderly men. Diabetologia 1997; 40: 344-347
11. Burlon PM, Billaudel B, Fauire-Dussert A. Influence of vitamin D3 deficiency and 1,25 dihydroxyvitamin D3 on de novo insulin biosynthesis in the islets of the rat endocrine pancreas. J Endocrinol 1999; 160: 87-95
12. London GM, Marchais SJ, Guérin AP et al. Association of bone activity, calcium load, aortic stiffness, and calcifications in ESRD. J Am Soc Nephrol 2008; 19: 1827-1835
13. Morosetti M, Jankovic L, Palombo G et al. High-dose calcitriol therapy and progression of cardiac vascular calcifications. J Nephrol 2008; 21: 603-608
14. Teng M, Wolf M, Amdahl et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 2005; 16: 1115-1125
15. Tentori F, Hunt WC, Stidley CA et al. Medical Directors of Dialysis Clinic Inc Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int 2006; 70(10): 1858-1865
16. Shoji T, Shinohara K, Kimoto E et al. Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D3 users in a haemodialysis population. Nephrol Dial Transplant 2004; 19: 179-184
17. Kovesdy CP, Ahmadzadeh S, Anderson JE et al. Association of activated vitamin D treatment and mortality in chronic kidney disease. Arch Intern Med 2008; 168: 397-403
18. Goodman WG, Coburn JW. The use of 1,25-dihydroxyvitamin D3 in early renal failure. Annu Rev Med 1992; 43: 227-237
19. Coen G, Mazzaferro S, Manni M et al. No acceleration and possibly slower progression of renal failure during calcitriol treatment in predialysis chronic renal failure. Nephrol Dial Transplant 1994; 9: 1520
20. Agarwal R, Acharya M, Tian J et al. Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int 2005; 68: 2823-2828
21. Mizobuchi M, Morrissey J, Finch JL et al. Combination therapy with an angiotensin-converting enzyme inhibitor and a vitamin D analog suppresses the progression of renal insufficiency in uremic rats. J Am Soc Nephrol 2007; 18: 1796-1806
22. Shoben AB, Rudser KDD, de Boer IH et al. Association of oral calcitriol with improved survival in nondialyzed CKD. J Am Soc Nephrol 2008; 19: 1613-1619
23. Naves-Díaz M, Alvarez-Hernández D, Passlick-Deetjen J et al. Oral active vitamin D is associated with improved survival in hemodialysis patients. Kidney Int 2008; 78(8): 1070-1078
24. Melamed ML, Michos ED, Post W et al. 25-hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med 2008; 168: 1629-1637